22 August 2016 in Proceedings of the National Academy of Sciences
Significance: Gas-filled microbubbles physically oscillate in an ultrasound field and have been shown to potentiate the delivery of therapeutic payloads. The biophysical mechanisms by which vibrating microbubbles stimulate macromolecule uptake across the cell membrane, however, remain unknown. With a coupled microscopy system capable of bright-field imaging up to 25 million frames per second, we show correlations between microsecond-scale bubble oscillations and second-to-minute–scale macromolecule diffusion, uniquely highlighting that microbubble-induced shear stress is a threshold indicator for membrane pore generation. Further insight into membrane reorganization using real-time confocal microscopy demonstrates that ultrasound-triggered microbubbles create resealing pores through both layers of cellular membrane, and gaps between confluent cells. This work presents mechanistic, biophysical insight into sonoporation as a tool for local delivery of therapeutic macromolecules.
29 November 2012 in Cancer Research
Microbubble contrast agents can specifically deliver nucleic acids to target tissues when exposed to ultrasound treatment parameters that mediate microbubble destruction. In this study, we evaluated whether microbubbles and ultrasound-targeted microbubble destruction (UTMD) could be used to enhance delivery of EGF receptor (EGFR)–directed siRNA to murine squamous cell carcinomas. Custom-designed microbubbles efficiently bound siRNA and mediated RNAse protection. UTMD-mediated delivery of microbubbles loaded with EGFR-directed siRNA to murine squamous carcinoma cells in vitro reduced EGFR expression and EGF-dependent growth, relative to delivery of control siRNA. Similarly, serial UTMD-mediated delivery of EGFR siRNA to squamous cell carcinoma in vivo decreased EGFR expression and increased tumor doubling time, relative to controls receiving EGFR siRNA-loaded microbubbles but not ultrasound or control siRNA-loaded microbubbles and UTMD. Taken together, our results offer a preclinical proof-of-concept for customized microbubbles and UTMD to deliver gene-targeted siRNA for cancer therapy. Cancer Res; 72(23); 6191–9. ©2012 AACR.
1 March 2011 in Ultrasound in Medicine & Biology
1 January 2015 in Theranostics
Signal transducer and activator of transcription 3 (STAT3) is constitutively activated in many cancers where it acts to promote tumor progression. A STAT3-specific transcription factor decoy has been developed to suppress STAT3 downstream signaling, but a delivery strategy is needed to improve clinical translation. Ultrasound-targeted microbubble destruction (UTMD) has been shown to enhance image-guided local delivery of molecular therapeutics to a target site. The objective of this study was to deliver STAT3 decoy to squamous cell carcinoma (SCC) tumors using UTMD to disrupt STAT3 signaling and inhibit tumor growth. Studies performed demonstrated that UTMD treatment with STAT3 decoy-loaded microbubbles inhibited STAT3 signaling in SCC cells in vitro. Studies performed in vivo demonstrated that UTMD treatment with STAT3 decoy-loaded microbubbles induced significant tumor growth inhibition (31-51% reduced tumor volume vs. controls, p < 0.05) in mice bearing SCC tumors. Furthermore, expression of STAT3 downstream target genes (Bcl-xL and cyclin D1) was significantly reduced (34-39%, p < 0.05) in tumors receiving UTMD treatment with STAT3 decoy-loaded microbubbles compared to controls. In addition, the quantity of radiolabeled STAT3 decoy detected in tumors eight hours after treatment was significantly higher with UTMD treatment compared to controls (70-150%, p < 0.05). This study demonstrates that UTMD can increase delivery of a transcription factor decoy to tumors in vivo and that the decoy can inhibit STAT3 signaling and tumor growth. These results suggest that UTMD treatment holds potential for clinical use to increase the concentration of a transcription factor signaling inhibitor in the tumor.
1 March 2016 in Ultrasound in Medicine & Biology
3 December 2015 in Molecular Pharmaceutics